2 active not recruiting, 2 not yet recruiting, 2 recruiting, 1 available. 4 Phase 2, 2 Phase 3, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 4 | Not yet recruiting 2, Active not recruiting 1, Recruiting 1 |
| Phase 3 | 2 | Active not recruiting 1, Recruiting 1 |
| Phase 1 | 1 | Active not recruiting 1 |
Follow zipalertinib: new trials by email Literature Review of zipalertinib trials Research Report on zipalertinib
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Zipalertinib With Carboplatin and Pemetrexed for the Treatment of Resectable, Stage II-IIIB, Non-Small Cell Lung Cancer Biospecimen Collection, Carboplatin, Computed Tomography - Lung Non-Squamous Non-Small Cell Carcinoma | Phase 2 | Not yet recruiting | Jonsson Comprehensive Cancer Center | 16 | 2027-06-01 | 2026-02-05 |
| Adjuvant ctDNA-Adapted Treatment With Zipalertinib in Early-Stage Atypical EGFR-Mutant NSCLC Zipalertinib - EGFR, Lung Cancer (NSCLC) | Phase 2 | Not yet recruiting | Stanford University | 42 | 2026-11-01 | 2026-09-03 |
| A Study to Assess Zipalertinib Versus Placebo in Participants With Early Stage NSCLC With Uncommon EGFR Mutations, Following Complete Tumor Resection TAS6417, Zipalertinib Matching-placebo - Lung Cancer, Adjuvant | Phase 3 | Recruiting | Taiho Oncology, Inc. | 360 | 2025-12-22 | 2026-10-13 |
| REZILIENT3 (REsearching ZIpaLertinib In Egfr Non-small Cell Lung Cancer Tumors) TAS6417 - Advanced or Metastatic NSCLS With Exon 20 Insertion Mutation | Phase 3 | Active not recruiting | Taiho Oncology, Inc. | 285 | 2023-12-18 | 2026-11-03 |
| A Study of Zipalertinib in Patients With Advanced Non-Small Cell Lung Cancer With Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertions or Other Uncommon Mutation. TAS6417, CYP Cocktail, Transporter Cocktail - Advanced or Metastatic NSCLC Harboring Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion (ex20ins) Mutations | Phase 2 | Recruiting | Taiho Oncology, Inc. | 220 | 2023-07-31 | 2026-10-06 |
| A Phase 1/2 Trial of CLN-081 in Patients With Non-Small Cell Lung Cancer CLN-081 - Non Small Cell Lung Cancer, EGFR Exon 20 Mutation | Phase 1 / Phase 2 | Active not recruiting | Cullinan Therapeutics Inc. | 284 | 2019-10-31 | 2026-06-17 |
| An EAP Treatment Protocol of Zipalertinib Zipalertinib - Non-Small Cell Lung Cancer | Available | Taiho Oncology, Inc. | 2026-06-11 |
Carcinoma, Non-Small-Cell Lung (5) · Lung Diseases (2) · Lung Neoplasms (2) · Carcinoma (1)
Taiho Oncology, Inc. (4) · Cullinan Therapeutics Inc. (1) · Jonsson Comprehensive Cancer Center (1) · Stanford University (1)
United States (5) · Italy (4) · Japan (4) · South Korea (4) · Spain (4) · Canada (3) · France (3) · Germany (3) · Hong Kong (3) · Netherlands (3) · Singapore (3) · Turkey (Türkiye) (3) · United Kingdom (3) · Australia (2) · Belgium (2)
Arjan Gower, MD (1) · Joel Neal, MD (1) · Zosia Piotrowska, MD (1)
PMID 33122578, PMID 37384848, PMID 39957151, PMID 40450572
2023 (2), 2025 (1)